Use of [177Lu]Lu-DOTA-TATE in the treatment of gastroenteropancreatic neuroendocrine tumours: Results of a UK cost-effectiveness modelling study

Use of [177Lu]Lu-DOTA-TATE in the treatment of gastroenteropancreatic neuroendocrine tumours: Results of a UK cost-effectiveness modelling study

Aim: To evaluate the cost-effectiveness of [177Lu]Lu-DOTA-TATE versus relevant comparators for the treatment of neuroendocrine tumours located in the gastrointestinal tract (GI-NETs) and the pancreas (P-NETs). Materials and methods: A three-state partitioned survival model was developed to perform a...

Full description

Bibliographic Details
Main Authors: Matthew Glover, Martyn Caplin, Oscar R. Leeuwenkamp, Louise Longworth
Format: Article
Language:English
Published: Elsevier 2021-11-01
Series:EJC Supplements
Subjects:
Gastro-enteropancreatic neuroendocrine tumours (GEP-NETs)
177Lu-DOTA-octreotate
[177Lu]Lu-DOTA-TATE
Everolimus
Sunitinib
Quality-Adjusted Life Years (QALYs)
Online Access:http://www.sciencedirect.com/science/article/pii/S1359634921000033

Internet

http://www.sciencedirect.com/science/article/pii/S1359634921000033

Similar Items